top of page

Process
Technology
Partnerships
Case Studies & Pipeline
News
Contact
About
More

Use tab to navigate through the menu items.

Qubigen data representation

News

Subscribe to Newsletter

Qubigen Signs Agreement with SyzOnc to Apply AI-Driven Drug Development to Promising Oncology Targets

Qubigen Signs Agreement with SyzOnc to Apply AI-Driven Drug Development to Promising Oncology Targets

Qubigen Signs Agreement with SyzOnc to Apply AI-Driven Drug Development to Promising Oncology Targets

Qubigen is pleased to announce the signing of an agreement with SyzOnc , an oncology-focused biotech company advancing novel approaches...

Sep 152 min read

Qubigen Signs Data Access Agreement with Flinders University

Qubigen Signs Data Access Agreement with Flinders University

Qubigen Signs Data Access Agreement with Flinders University

Qubigen is pleased to announce the signing of a Data Access Master Agreement with Flinders University , establishing a framework for...

Sep 42 min read

Qubigen Co-Founder Dr Jun Zeng Elected Fellow of the Royal Australian Chemical Institute (FRACI)

Qubigen Co-Founder Dr Jun Zeng Elected Fellow of the Royal Australian Chemical Institute (FRACI)

Qubigen Co-Founder Dr Jun Zeng Elected Fellow of the Royal Australian Chemical Institute (FRACI)

Qubigen is proud to announce that Dr Jun Zeng, Co-Founder and Chief Information Officer, has been elected as a Fellow of the Royal...

Sep 41 min read

enquiries@qubigen.com

Bio21 Institute

30 Flemington Road

Parkville VIC 3052

Australia

Accelerate drug design
without exposing secrets

Connect with Us

© 2025 Qubigen. All rights reserved.

bottom of page